Rolapitant treats lung cancer by targeting deubiquitinase OTUD3.

导出 OA

翻译打印收藏纠错

作者： Tongde,Du ^[1] ; Quan,Gu ^[1] ; Yonghui,Zhang ^[2] ; Yujie,Gan ^[1] ; Rongrui,Liang ^[3] ; Wenzhu,Yang ^[4] ; Ya,Lu ^[1] ; Chenxin,Xu ^[1] ; Jianzhong,Wu ^[1] ; Rong,Ma ^[1] ; Haixia,Cao ^[1] ; Jingwei,Jiang ^[5] ; Juan,Wang ^[6] ; Jifeng,Feng ^[7]

作者单位： Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 210009, Jiangsu, China. ^[1] Senior Department of General Surgery, The First Medical Center, Chinese PLA General Hospital, Beijing, 100853, China. ^[2] Department of Oncology, The Fourth Affiliated Hospital of Soochow University, Medical Center of Soochow University, Suzhou, 215123, Jiangsu, China. ^[3] Department of Pediatrics, Chui Yang Liu Hospital Affiliated to Tsinghua University, Beijing, 100022, China. ^[4] Institute of Pharmacologic Science, China Pharmaceutical University, Nanjing, 210009, Jiangsu, China. jiangjingwei@cpu.edu.cn. ^[5] Department of Oncology, The Fourth Affiliated Hospital of Soochow University, Medical Center of Soochow University, Suzhou, 215123, Jiangsu, China. wang_juan_amanda@163.com. ^[6] Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 210009, Jiangsu, China. fjif@jszlyy.com.cn. ^[7]

关键词 Apoptosis DR5 Inhibitor Lung cancer OTUD3 Rolapitant